Li Zhou

Dr. Li Zhou


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2022 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
CWChun-Ying Wu
Chun-Ying Wu
GLGuan-Ting Li
Guan-Ting Li
CCChen-Chao Chu
Chen-Chao Chu
HGHong-Li Guo
Hong-Li Guo
WFWei-Rong Fang
Wei-Rong Fang
FCFeng Chen
Feng Chen

27 September 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
HGHong-Li Guo
Hong-Li Guo
YZYue-Tao Zhao
Yue-Tao Zhao
WWWei-Jun Wang
Wei-Jun Wang
NDNa Dong
Na Dong
YHYa-Hui Hu
Ya-Hui Hu
TLTao Li
Tao Li
Thiopurines, including thioguanine (TG), 6-mercaptopurine (6-MP), and azathioprine (AZA), are extensively used in clinical practice in children with acute lymphoblastic leukemia (ALL) and inflammatory bowel diseases. However, the common adverse effects caused by myelosuppression and hepatotoxicity limit their application. Metabolizing enzymes such as thiopurine S-methyltransferase (TPMT), nudix hydrolase 15 (NUDT15), inosine triphosphate pyrophosphohydrolase (ITPA), and drug transporters like multidrug resistance-associated protein 4 (MRP4) have been reported to mediate the metabolism and transportation of thiopurine drugs. Hence, the single nucleotide polymorphisms (SNPs) in those genes could theoretically affect the pharmacokinetics and pharmacological effects of these drugs, and might also become one of the determinants of clinical efficacy and adverse effects. Moreover, long-term clinical practices have confirmed that thiopurine-related adverse reactions are associated with the systemic concentrations of their active metabolites. In this review, we mainly summarized the pharmacogenetic studies of thiopurine drugs. We also evaluated the therapeutic drug monitoring (TDM) research studies and focused on those active metabolites, hoping to continuously improve monitoring strategies for thiopurine therapy to maximize therapeutic efficacy and minimize the adverse effects or toxicity. We proposed that tailoring thiopurine dosing based on MRP4, ITPA, NUDT15, and TMPT genotypes, defined as “MINT” panel sequencing strategy, might contribute toward improving the efficacy and safety of thiopurines. Moreover, the DNA-incorporated thioguanine nucleotide (DNA-TG) metabolite level was more suitable for red cell 6-thioguanine nucleotide (6-TGNs) monitoring, which can better predict the efficacy and safety of thiopurines. Integrating the panel “MINT” sequencing strategy with therapeutic “DNA-TG” monitoring would offer a new insight into the precision thiopurine therapy for pediatric acute lymphoblastic leukemia patients.

2 May 2024 in Translational Pediatrics
Verified
Journal Article
Open access
PDF file
JLJian Li
Jian Li
LHLulu He
Lulu He
QWQizi Wu
Qizi Wu
JZJianfeng Zhou
Jianfeng Zhou
LZLi Zhou
Li Zhou
TLTao Li
Tao Li
Background: Undifferentiated embryonal sarcoma of the liver (UESL) is a rare and highly aggressive malignancy predominantly affecting children and adolescents. Managing UESL is particularly intricate due to its aggressive nature and the limited array of treatment options available. This study is dedicated to elucidating the efficacy of a multimodal therapeutic strategy in the successful management of UESL. Case Description: Four pediatric patients (two males, two females; aged 6–11 years) diagnosed with UESL were treated at the Children’s Hospital of Nanjing Medical University between November 2019 and June 2023. Surgical resection with lymph node dissection achieved complete primary tumor eradication. Adjuvant chemotherapy tailored to each patient’s needs was followed by localized radiation therapy. After 9–42 months of follow-up, one patient who did not undergo immediate radiotherapy experienced a relapse. Following a second operation coupled with radiotherapy, the patient achieved complete remission, and mirroring the status of the other three patients who are now presently in remission. The overall cohort exhibited commendable tolerance to the treatment regimen, with manageable chemotherapy-related toxicities. Conclusions: This case series suggests that implementing a standardized protocol of resection, followed by adjuvant chemotherapy and radiation, can lead to favorable outcomes in pediatric patients diagnosed with UESL. Nevertheless, the need for comprehensive large-scale studies is imperative to substantiate the effectiveness of this approach.

1 August 2024 in Translational Pediatrics
Verified
Journal Article
Open access
PDF file
THTianjiao Hu
Tianjiao Hu
QWQizi Wu
Qizi Wu
JLJian Li
Jian Li
TLTao Li
Tao Li
XJXu Jin
Xu Jin
LZLi Zhou
Li Zhou
Background: Primary mediastinal choriocarcinoma (PCC) is a rare, highly vascular invasive, and prognostically unfavorable malignant tumor. When occurring outside the gonads, primary choriocarcinoma is commonly found in midline locations such as the mediastinum or retroperitoneum. Currently, there is no standardized treatment strategy for PCC. In the case reported herein, we employed tislelizumab and chemotherapy in the treatment of a patient with PCC, and as in March 2024, the patient remained survive. Case Description: A 15-year-old boy who presented with symptoms of fever and cough for a year. Chest computed tomography (CT) scan showed a relatively large soft tissue shadow in the right upper anterior mediastinum, measuring approximately 5.4 cm × 3.8 cm. The patient’s soft tissue exhibited unclear demarcation from surrounding mediastinal structures and was accompanied by lung metastasis. The patient underwent a fine needle aspiration biopsy for a mediastinal mass, and the pathology results indicated a germ cell tumor with solid malignant components in the mediastinum, along with pulmonary metastasis of the solid malignancy. The patient’s serum levels of beta-human chorionic gonadotropin (β-HCG) were elevated at 125,554 mIU/mL (normal range: <5 mIU/mL), and alpha-fetoprotein (AFP) was 75.8 ng/mL (normal range, 0.605–7 ng/mL). The patient’s cranial magnetic resonance imaging (MRI) plain scan indicated multiple scattered abnormal signals in both cerebral hemispheres. Subsequently, the patient was transferred to Children’s Hospital of Nanjing Medical University for his further treatment. During the treatment period, we employed various therapeutic approaches, including chemotherapy, radiotherapy and tislelizumab therapy. After five cycles of tislelizumab treatment, the patient’s symptoms of cerebral edema significantly improved, β-HCG levels decreased. Brain MRI of the patient revealed multiple abnormal signals within the skull, with some lesions showing reduction in size and significant improvement in the surrounding edema zones. The clinical symptoms of the patient improved and he achieved partial remission (PR). At the moment, the patient is living with the disease. Conclusions: The effectiveness of chemotherapy for PCC is limited. Tislelizumab may potentially serve as salvage treatment options for PCC.

4 August 2026 in Frontiers in Oncology
Verified
Journal Article
Open access
PDF file
THTianjiao Hu
Tianjiao Hu
JLJian Li
Jian Li
LHLulu He
Lulu He
XZXiaojun Zhang
Xiaojun Zhang
JXJin Xu
Jin Xu
LZLi Zhou
Li Zhou
Anti-Ganglioside (GD)2 monoclonal antibodies are widely used as maintenance therapy for high-risk neuroblastoma (HR-NB). However, the potential benefit of introducing immunotherapy during induction chemotherapy remains unclear. We report two pediatric patients with newly diagnosed HR-NB who received naxitamab in combination with chemotherapy starting from the second cycle of induction. Clinical characteristics, treatment regimens, and outcomes were retrospectively reviewed. Both patients achieved complete remission (CR) per International Neuroblastoma Response Criteria at the end of induction. Treatment-related adverse events, including hypotension, pain, and rash, capillary leak syndrome, and chemotherapy-related myelosuppression, were transient and manageable with supportive care and infusion adjustments. No treatment discontinuation due to toxicity occurred. While these preliminary findings demonstrate the feasibility and tolerability of early naxitamab introduction, the limited sample size precludes definitive conclusions regarding efficacy. This report provides exploratory data to support future prospective studies on optimizing the timing of anti-GD2 immunotherapy in HR-NB.

1 February 2026 in Translational Pediatrics
Verified
Journal Article
Open access
JLJian Li
Jian Li
MYMengwen Yan
Mengwen Yan
THTianjiao Hu
Tianjiao Hu
LWLei Wu
Lei Wu
CZChunlei Zhou
Chunlei Zhou
LZLi Zhou
Li Zhou
Congenital mesoblastic nephroma (CMN) is a rare renal tumor predominantly occurring in neonates and young infants, and standardized treatment guidelines remain lacking. This study aimed to summarize the clinical features, therapeutic strategies, and outcomes of CMN patients from a single institution to inform clinical practice. We retrospectively reviewed the medical records of nine children with pathologically and molecularly confirmed CMN treated at Children’s Hospital of Nanjing Medical University between 2015 and 2024. Demographic characteristics, clinical presentation, imaging findings, histological subtypes, gene fusions, treatment approaches, and follow-up data were analyzed. The median age at diagnosis was 2.5 months (range: newborn to 93 months), with a male-to-female ratio of 2:1. Most patients (90%) presented with an abdominal mass detected prenatally or incidentally. The tumor originated from the right kidney in seven cases and the left in two. Ultrasound and computed tomography (CT) commonly revealed mixed cystic-solid masses, with heterogeneous enhancement on contrast imaging. Pathological subtypes included cellular (n=5), classic (n=2), and mixed (n=2). Of seven patients undergoing fluorescence in situ hybridization (FISH), three were positive for the ETV6::NTRK3 fusion; four were negative; and two relapsed patients underwent next-generation sequencing (NGS), which identified TPM3::NTRK1 and EGFR-kinase domain duplication (EGFR-KDD), respectively. All patients underwent surgical resection with a 100% resection rate. Two relapsed patients received salvage chemotherapy [vincristine-actinomycin D-cyclophosphamide (VAC) or ifosfamide-carboplatin-etoposide (ICE)], which showed limited efficacy. One relapsed patient with TPM3::NTRK1 received larotrectinib but died two months later; another with EGFR-KDD experienced disease stabilization after afatinib plus programmed cell death protein 1 (PD-1) blockade following progression on entrectinib and anlotinib. After a median follow-up of 36 months (range: 12–115 months), the overall survival was 88.9%, and the event-free survival was 77.8%. This small single-center case series describes the clinical and molecular heterogeneity of CMN. While most patients experienced favorable outcomes following surgery, relapsed cases highlight the challenges associated with molecularly atypical disease. These observations are descriptive in nature and underscore the need for larger collaborative studies to better define prognostic factors and optimal management strategies in CMN.